NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced a chief financial officer succession plan, with Ron McClurg set to retire as CFO effective June 30, 2026. McClurg will remain with the company as a Senior Advisor through December 31, 2026, to ensure a smooth transition. Chris Volker, the company’s current Chief Operating Officer, will assume the role of CFO on a permanent basis, while David Wambeke, newly appointed Chief Business Officer, will take over many of Volker’s previous responsibilities.
The leadership change comes as NeuroOne continues to advance its medical technology platform for neurological disorders. The company markets minimally invasive electrode technologies with four FDA-cleared product families, including Evo® Cortical Electrodes and the OneRF® Ablation System. The transition is intended to maintain financial and operational momentum as the company pursues growth in its product pipeline and commercial expansion.
Dave Rosa, CEO of NeuroOne, expressed gratitude for McClurg’s service. “On behalf of the entire NeuroOne organization, I want to express our sincere gratitude to Ron for more than five years of outstanding service and the meaningful contributions he has made to the Company,” Rosa said. “Ron’s retirement marks the culmination of a long and successful career, and we are grateful for his leadership, stewardship, and commitment to NeuroOne. We are also fortunate that he will remain actively involved as a Senior Advisor to help ensure a smooth transition.”
Rosa also highlighted Volker’s qualifications. “We are pleased to also announce the appointment of Chris Volker as our next Chief Financial Officer. Chris brings deep leadership experience across medtech, finance, strategy and commercial operations, and I believe he is the right person to step into this role as we continue advancing NeuroOne’s technologies and growth strategy.”
Volker brings more than 25 years of operational and financial leadership in the medical device industry. He is a CFA® charterholder and earned his MBA from The Wharton School of the University of Pennsylvania. His experience includes senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International, overseeing international P&L and commercial expansion. Prior to that, he held executive leadership roles at St. Jude Medical, reporting directly to the CFO. He began his career in healthcare and technology investment banking at Dain Rauscher.
McClurg reflected on his tenure. “It has been a privilege to serve as NeuroOne’s Chief Financial Officer for over five years and to work alongside such a talented team. I am proud of this team and the benefits our products are providing for patients. After many rewarding years in the industry, I have decided the time is right for me to retire. I remain fully committed to supporting NeuroOne through this transition period and look forward to working closely with Chris and the leadership team.”
Volker added, “I am honored to take on the role of Chief Financial Officer and appreciate the confidence the Board and the management team have placed in me. NeuroOne has built strong momentum, both in advancing our product pipeline and commercially, and I look forward to working closely with the team, as well as with Ron during this transition, to support the Company’s strategic, operational, and financial objectives.”
The succession plan underscores NeuroOne’s focus on maintaining stability while pursuing growth. The company is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
